home / stock / bcab / bcab news

BCAB News and Press, BioAtla Inc. From 03/26/24

Stock Information
Company Name: BioAtla Inc.
Stock Symbol: BCAB
Market: NASDAQ
Website: bioatla.com
Menu
BCAB BCAB Quote BCAB Short BCAB News BCAB Articles BCAB Message Board
Get BCAB Alerts

News, Short Squeeze, Breakout and More Instantly...
BCAB - Expected US Company Earnings on Tuesday, March 26th, 2024

Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...
BCAB - BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024

SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference c...

BCAB - BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Five abstracts accepted for poster presentation highlight Company’s proprietary Conditionally Active Biologic (CAB) technology Differentiated preclinical activity for CAB anti-Nectin4-antibody drug conjugate (ADC) with superior efficacy to enfortumab vedotin analogue in a patient d...

BCAB - DWAC, OCUL and APPF are among after hour movers

2024-01-25 16:59:42 ET Gainers: Ocular Therapeutix,  ( OCUL ) +5% . AppFolio ( APPF ) +4% . Sagimet Biosciences  ( SGMT ) +3% . Xcel Energy  ( XEL ) +3% . Digital World Acquisition  ( DWAC ) +2% . Losers...
BCAB - BioAtla CEO purchases 50K common shares

2023-12-21 11:18:41 ET More on BioAtla BioAtla, Inc. (BCAB) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on BioAtla For further details see: BioAtla CEO purchases 50K common shares

BCAB - BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management ...

BCAB - BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types

Multiple confirmed responses and durable disease control observed Emerging differentiated safety profile enables further exploration at higher doses Ongoing Phase 2 clinical study of monotherapy and in combination with a PD-1 inhibitor SAN DIEGO, Dec. 13, 2023 (GLOBE NEWSW...
BCAB - BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023

SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced it will host a virtual R&D Da...

BCAB - BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event

Results from the Phase 2 BA3011 clinical non-small cell lung cancer (NSCLC) study demonstrated promising clinical benefits in heavily pre-treated non-squamous histology patients across key endpoints BA3011 is a CAB-AXL antibody-drug conjugate (ADC) being studied in refractory NSCLC pati...

BCAB - BCAB, DUNE and CDT among mid-day movers

2023-12-04 12:47:12 ET Gainers: Hawaiian Holdings ( HA ) +187% . EyePoint Pharmaceuticals ( EYPT ) +177% . SilverSun Technologies ( SSNT ) +176% . Alterity Therapeutics Ltd ( ATHE ) +122% . View ( VIEW ) +82% . enGene Holding...
Previous 10 Next 10